| Year |
Citation |
Score |
| 2019 |
McDonnell AM, Pyles HM, Diaz-Cruz ES, Barton CE. Enoxacin and Epigallocatechin Gallate (EGCG) Act Synergistically to Inhibit the Growth of Cervical Cancer Cells in Culture. Molecules (Basel, Switzerland). 24. PMID 31013600 DOI: 10.3390/Molecules24081580 |
0.364 |
|
| 2012 |
Miermont AM, Cabrera MC, Frech SM, Nakles RE, Diaz-Cruz ES, Shiffert MT, Furth PA. Association of Over-Expressed Estrogen Receptor Alpha with Development of Tamoxifen Resistant Hyperplasia and Adenocarcinomas in Genetically Engineered Mice. Anatomy & Physiology : Current Research. PMID 24575359 |
0.357 |
|
| 2012 |
Cabrera MC, Díaz-Cruz ES, Kallakury BV, Pishvaian MJ, Grubbs CJ, Muccio DD, Furth PA. The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway. Cancer Prevention Research (Philadelphia, Pa.). 5: 810-21. PMID 22508966 DOI: 10.1158/1940-6207.Capr-11-0532-T |
0.343 |
|
| 2011 |
Furth PA, Nakles RE, Millman S, Diaz-Cruz ES, Cabrera MC. Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer. Breast Cancer Research : Bcr. 13: 220. PMID 22018398 DOI: 10.1186/Bcr2921 |
0.313 |
|
| 2011 |
Díaz-Cruz ES, Sugimoto Y, Gallicano GI, Brueggemeier RW, Furth PA. Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer Cancer Research. 71: 5477-5487. PMID 21840986 DOI: 10.1158/0008-5472.CAN-10-4652 |
0.704 |
|
| 2011 |
Furth PA, Cabrera MC, Díaz-Cruz ES, Millman S, Nakles RE. Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models. Annals of the New York Academy of Sciences. 1229: 147-55. PMID 21793850 DOI: 10.1111/J.1749-6632.2011.06086.X |
0.6 |
|
| 2011 |
Nakles RE, Shiffert MT, Díaz-Cruz ES, Cabrera MC, Alotaiby M, Miermont AM, Riegel AT, Furth PA. Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content. Molecular Endocrinology (Baltimore, Md.). 25: 549-63. PMID 21292825 DOI: 10.1210/me.2010-0114 |
0.568 |
|
| 2010 |
Diaz-Cruz ES, Cabrera MC, Nakles R, Rutstein BH, Furth PA. BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer. Breast Disease. 32: 85-97. PMID 21778574 DOI: 10.3233/Bd-2010-0308 |
0.429 |
|
| 2008 |
Su B, Díaz-Cruz ES, Landini S, Brueggemeier RW. Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition. Steroids. 73: 104-11. PMID 18045633 DOI: 10.1016/J.Steroids.2007.09.011 |
0.771 |
|
| 2008 |
Davis DD, Díaz-Cruz ES, Landini S, Kim YW, Brueggemeier RW. Evaluation of synthetic isoflavones on cell proliferation, estrogen receptor binding affinity, and apoptosis in human breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 108: 23-31. PMID 17962013 DOI: 10.1016/J.Jsbmb.2007.07.001 |
0.747 |
|
| 2008 |
Diaz-Cruz E, Furth P, Brueggemeier R, Sugimoto Y. Abstract B70: A conditional aromatase over-expressing in the mammary gland transgenic mouse as a potential model in cancer prevention research Cancer Prevention Research. 1. DOI: 10.1158/1940-6207.Prev-08-B70 |
0.696 |
|
| 2007 |
Brueggemeier RW, Su B, Sugimoto Y, Díaz-Cruz ES, Davis DD. Aromatase and COX in breast cancer: enzyme inhibitors and beyond. The Journal of Steroid Biochemistry and Molecular Biology. 106: 16-23. PMID 17616393 DOI: 10.1016/J.Jsbmb.2007.05.021 |
0.774 |
|
| 2006 |
Díaz-Cruz ES, Brueggemeier RW. Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer. Anti-Cancer Agents in Medicinal Chemistry. 6: 221-32. PMID 16712450 DOI: 10.2174/187152006776930873 |
0.785 |
|
| 2006 |
Su B, Diaz-Cruz ES, Landini S, Brueggemeier RW. Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. Journal of Medicinal Chemistry. 49: 1413-9. PMID 16480277 DOI: 10.1021/Jm051126F |
0.793 |
|
| 2005 |
Su B, Hackett JC, Díaz-Cruz ES, Kim YW, Brueggemeier RW. Lead optimization of 7-benzyloxy 2-(4'-pyridylmethyl)thio isoflavone aromatase inhibitors. Bioorganic & Medicinal Chemistry. 13: 6571-7. PMID 16125392 DOI: 10.1016/J.Bmc.2005.07.038 |
0.747 |
|
| 2005 |
Brueggemeier RW, Díaz-Cruz ES, Li PK, Sugimoto Y, Lin YC, Shapiro CL. Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. The Journal of Steroid Biochemistry and Molecular Biology. 95: 129-36. PMID 15964185 DOI: 10.1016/J.Jsbmb.2005.04.013 |
0.765 |
|
| 2005 |
Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocrine Reviews. 26: 331-45. PMID 15814851 DOI: 10.1210/Er.2004-0015 |
0.753 |
|
| 2005 |
Díaz-Cruz ES, Shapiro CL, Brueggemeier RW. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. The Journal of Clinical Endocrinology and Metabolism. 90: 2563-70. PMID 15687328 DOI: 10.1210/Jc.2004-2029 |
0.768 |
|
| 2002 |
Coleman RS, Burk CH, Navarro A, Brueggemeier RW, Diaz-Cruz ES. Role of the azinomycin naphthoate and central amide in sequence-dependent DNA alkylation and cytotoxicity of epoxide-bearing substructures. Organic Letters. 4: 3545-8. PMID 12323065 DOI: 10.1021/Ol0267275 |
0.611 |
|
| Show low-probability matches. |